Abstract:Abstract Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.

Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization

Immunosenescence: a key player in cancer development

Characteristics and mechanisms of T-cell senescence: A potential target for cancer immunotherapy

T Cell Senescence and CAR-T Cell Exhaustion in Hematological Malignancies

T-cell immunity against senescence: potential role and perspectives

Benefit delayed immunosenescence by regulating CD4+T cells: A promising therapeutic target for aging‐related diseases

Immunosenescence: molecular mechanisms and diseases

Are immunosenescent T cells really senescent?

T-cell Immunoglobulin and ITIM Domain Contributes to CD8+ T-cell Immunosenescence.

Regulation of telomerase towards tumor therapy

T cell senescence: a new perspective on immunotherapy in lung cancer

Senescent T cells: a potential biomarker and target for cancer therapy

Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and Mirnas

Impact and potential value of immunosenescence on solid gastrointestinal tumors

An in-depth understanding of the role and mechanisms of T cells in immune organ aging and age-related diseases

Transient Induction of Telomerase Expression Mediates Senescence and Reduces Tumorigenesis in Primary Fibroblasts.

A silver bullet for ageing medicine?: clinical relevance of T-cell checkpoint receptors in normal human ageing

Immunosenescence and cancer: Opportunities and challenges

Immunosenescence: A new direction in anti-aging research

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

Immunosenescence: participation of T lymphocytes and myeloid-derived suppressor cells in aging-related immune response changes